Table 1. Clinical characteristics and corresponding engraftment rates.
| Tumor Characteristics | Engraftment success | P value | |
|---|---|---|---|
| n (%) | |||
| No | Yes | ||
| Histology | |||
| IDC | 113 (89) | 14 (11) | 0.006 |
| ILC | 4 (100) | 0 (0) | |
| Metaplasic | 0 (0) | 3 (100) | |
| Others | 3 (100) | 0 (0) | |
| Grade | |||
| II | 55 (98.2) | 1 (1.7) | 0.001 |
| III | 65 (80.2) | 16 (19.7) | |
| Estrogen Receptor | |||
| Negative | 32 (74.4) | 11 (25.5) | 0.004 |
| Positive | 88 (93.6) | 6 (6.3) | |
| Progesterone Receptor | |||
| Negative | 58 (80.5) | 14 (19.4) | 0.009 |
| Positive | 62 (95.3) | 3 (4.6) | |
| HER2 | |||
| Negative | 82 (86.3) | 13 (13.6) | 0.58 |
| Positive | 38 (90.4) | 4 (9.5) | |
| Ki-67 | |||
| Low (< 20) | 27 (100) | 0 (0) | 0.02 |
| High (> 20) | 93 (84.5) | 17 (15.4) | |
| Subtype | |||
| Luminal A | 14 (100) | 0 (0) | 0.020 |
| Luminal B HER2 - | 43 (93.4) | 3 (6.5) | |
| Luminal B HER2 + | 33 (91.6) | 3 (8.3) | |
| HER2 + | 5 (83.3) | 1 (16.6) | |
| Triple negative | 25 (71.4) | 10 (28.5) | |
| Stage | |||
| IA | 29 (100) | 0(0) | 0.04 |
| IB | 3 (75) | 1 (25) | |
| IIA | 37 (88.1) | 5 (11.9) | |
| IIB | 28 (87.5) | 4 (12.5) | |
| III | 19 (79.1) | 5 (20.8) | |
| IV | 4 (66.6) | 2 (33.3) | |
| BRCA | |||
| No | 118 (90.08) | 13 (9.9) | 0.002 |
| Yes | 2 (33.3) | 4 (66.6) | |
| Neoadjuvant Treatment | |||
| NO | 99 (92.5) | 8 (7.4) | 0.002 |
| YES | 20 (68.9) | 9 (31.03) |